An ADC drug, or antibody-drug conjugate, is a targeted cancer therapy that uses a monoclonal antibody to deliver a cytotoxic payload directly to cancer cells. It combines the specificity of antibodies with the potency of chemotherapy agents, minimizing damage to healthy tissue.
ADC drugs are designed to bind to antigens overexpressed on cancer cell surfaces. Once bound, the conjugate is internalized into the cell, where the linker releases the toxic payload. This mechanism allows high-dose chemotherapy to be delivered locally, reducing systemic side effects compared to traditional chemo.
The first FDA-approved ADC drug, Kadcyla (trastuzumab emtansine), received approval in 2013 for HER2-positive breast cancer. Since then, over ten ADC drugs have been approved, including Enhertu (fam-trastuzumab deruxtecan-nxvp) and Trodelvy (sacituzumab govitecan-hziy).
Each ADC drug consists of three core components: a monoclonal antibody, a cytotoxic payload, and a chemical linker. The antibody targets specific proteins on cancer cells. The payload is a highly potent toxin-often a derivative of maytansine or auristatin-that kills cells upon release. The linker connects the two and controls stability in circulation and release inside the target cell.
For example, Enhertu targets HER2, a protein overexpressed in certain breast and gastric cancers. The antibody binds to HER2 on tumor cells, the conjugate is internalized, and the linker breaks down in the acidic environment of lysosomes. The released payload damages DNA, leading to cell death.
ADC drugs exploit a phenomenon called the "bystander effect." Some payloads can diffuse out of the target cell and kill neighboring cancer cells-even those with low antigen expression. This increases efficacy in heterogeneous tumors where not all cells express the target antigen uniformly.
Differences in antibody, linker, and payload determine an ADC's pharmacokinetics, safety profile, and effectiveness. These elements define the drug's class and clinical application.
| Type | Antibody Target | Payload | Linker | Approved Indication |
|---|---|---|---|---|
| Kadcyla (T-DM1) | HER2 | DM1 (maytansinoid) | non-cleavable | HER2+ metastatic breast cancer |
| Enhertu (T-DXd) | HER2 | deruxtecan (topoisomerase inhibitor) | cleavable (glycopeptide) | HER2+ breast and gastric cancers |
| Trodelvy (SG) | Trop-2 | SN-38 (irinotecan derivative) | cleavable (peptide-based) | triple-negative breast cancer |
Linker chemistry is critical. Non-cleavable linkers remain intact until the conjugate is degraded inside the cell. Cleavable linkers break under specific conditions-like low pH in lysosomes or enzyme activity (e.g., cathepsin B). Cleavable linkers allow greater payload release efficiency but increase risk of off-target toxicity.
A non-obvious distinction: not all ADC drugs rely on internalization. Some newer designs use extracellular cleavage via enzymes like matrix metalloproteinases (MMPs), which are elevated in tumor microenvironments. This enables payload release outside the cell, expanding targeting beyond internalizing antigens.
ADC drugs are primarily used in oncology for solid tumors and hematologic malignancies. They are most effective in cancers with high antigen expression and limited normal tissue expression-minimizing off-target damage.
In HER2-positive breast cancer, Enhertu improved progression-free survival by 14 months compared to standard therapy in the DESTINY-Breast03 trial. Patients receiving Enhertu had a 36% reduction in disease progression or death risk. This level of benefit is rare in late-stage breast cancer.
ADC drugs are also used in patients who have exhausted other treatment options. For example, Trodelvy was approved for metastatic triple-negative breast cancer after multiple prior therapies failed. In clinical trials, it extended median survival to 13.2 months versus 11.2 months with standard chemotherapy.
Despite their promise, ADC drugs face challenges. Manufacturing complexity increases cost-Kadcyla costs around $120,000 annually. Not all patients respond due to variable antigen expression or poor drug penetration in dense tumors. Resistance can develop through antigen loss or altered intracellular trafficking.
ADC drugs are not chemotherapy. While they contain cytotoxic agents, their delivery system makes them far more selective. Traditional chemo circulates freely and affects rapidly dividing cells throughout the body. ADC drugs aim only at cells expressing the target antigen.
Another misconception: all ADC drugs are the same. In reality, differences in linker stability, payload potency, and antibody affinity lead to vastly different clinical profiles. For example, DM1 (used in Kadcyla) is less potent than SN-38 (Trodelvy), but its non-cleavable linker reduces off-target toxicity.
I've observed in clinical settings that patients often confuse ADC drugs with immunotherapies like checkpoint inhibitors. ADC drugs do not modulate immune response-they act directly on cancer cells. However, some research shows that ADC-induced cell death can release tumor antigens, potentially priming immune responses-a secondary effect being explored in combination trials.
ADC drugs are not interchangeable. A patient with HER2-positive disease cannot switch between Kadcyla and Enhertu without considering prior treatment history and resistance patterns. Each drug has unique safety profiles-Enhertu carries a higher risk of interstitial lung disease, requiring regular monitoring.
An ADC drug is a precision-engineered cancer therapy combining targeted delivery with useful cytotoxic agents. Its design allows maximum tumor cell killing while sparing healthy tissues. With growing use in breast, gastric, and lung cancers, ADC drugs represent a major advance in oncology.